PTAB Knocks Out Two Copaxone 40 mg Patents
Executive Summary
Patent Trial and Appeal Board finds claims in '250 and '413 patents covering 40 mg dosage are unpatentable, giving generic manufacturers a chance at early entry once FDA approves ANDAs.
You may also be interested in...
Fate Of Copaxone 40mg Patents Depends On Courts After PTAB Rejection
Teva awaits district court ruling on patents covering the three-times-a-week dosage and is appealing the Patent Trial & Appeal Board’s findings of unpatentability.
Stockwatch: Teva And Mylan Hit Terminal Velocity
Another social media jump on the drug pricing bandwagon by Hillary Clinton directed at Mylan's EpiPen pricing policy temporarily sank most life science stock prices last week. Fortunately, the lasting impact should be limited to Teva and Mylan.
Mylan Sees A Difference In Having Generic Drug User Fees
FDA is pushing forward with its review of Mylan’s ANDA for generic Advair, according to the company, which is gaining confidence that the application could receive a first round approval. The experience for that application, which has a generic drug user fee, is a clear contrast to the firm's experience with its pre-GDUFA Copaxone filing.